Canagliflozin: Research, Dosing, and Where to Buy in 2026
A research-first profile for Canagliflozin (SGLT2 inhibitor), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Canagliflozin is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Canagliflozin, each linked to its source.
- Also indexed as SGLT2 inhibitor.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Canagliflozin?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Canagliflozin Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Canagliflozin in 2026
No tracked vendor recommendations for Canagliflozin yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Canagliflozin. Each line links to the original source.
- "Total fat mass (baseline 33.2 kg) was reduced by 3.4 kg and 2.6 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: -0.79 [95% CI -2.10, 0.51])." · McCrimmon R et al, 2020 PubMed
- "Eligible patients were at least 18 years old and had uncontrolled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) on stable daily metformin therapy." · Lingvay I et al, 2019 PubMed
- "Premature treatment discontinuation because of adverse events occurred in 38 (10%) of 392 patients with semaglutide and in 20 (5%) of 394 patients with canagliflozin." · Lingvay I et al, 2019 PubMed
- "People with type 2 diabetes and an HbA1c of 7·0-10·5% (53-91 mmol/mol) who were aged at least 30 years and had a history of symptomatic atherosclerotic vascular disease, or who were aged at least 50 years and had at least two cardiovascular risk factors were eligible to participate." · Perkovic V et al, 2018 PubMed
- "Annual eGFR decline was slower (slope difference between groups 1·2 mL/min per 1·73 m2 per year, 95% CI 1·0-1·4) and mean UACR was 18% lower (95% CI 16-20) in participants treated with canagliflozin than in those treated with placebo." · Perkovic V et al, 2018 PubMed
- "Total serious renal-related adverse events were similar between the canagliflozin and placebo groups (2·5 vs 3·3 per 1000 patient-years; HR 0·76, 95% CI 0·49-1·19)." · Perkovic V et al, 2018 PubMed
- "Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all P<0.001)." · Rådholm K et al, 2018 PubMed
- "The benefit on cardiovascular death or hospitalized HF may be greater in patients with a prior history of HF (HR, 0.61; 95% CI, 0.46-0.80) compared with those without HF at baseline (HR, 0.87; 95% CI, 0.72-1.06; P interaction =0.021)." · Rådholm K et al, 2018 PubMed
Research and Studies
8 PubMed-indexed papers reference Canagliflozin. Top 8 shown.
Legal Status
Canagliflozin is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Canagliflozin FDA-approved?
Canagliflozin is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Canagliflozin?
8 PubMed-indexed paper(s) reference Canagliflozin in our current research feed. See the Research and Studies section above for citations.